By Julie Steenhuysen CHICAGO (Reuters) – Gene sequencing company Illumina Inc is going after the next big advance in cancer detection, working to develop a universal blood test to identify early-stage cancers in people with no symptoms of the disease. On Sunday, San Diego-based Illumina said it would form a new company, called Grail, with more than $100 million in Series A financing. Illumina will be the majority owner.
View original here:
Illumina, partners make $100 million bet to detect cancer via blood test